CA-IKOTEK
29.9.2022 15:01:38 CEST | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/
Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire)
Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception.
Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy across program management, R&D, sourcing, testing and production at its own as well as third party manufacturing facilities to produce designs for our customers. With a wide variety IoT projects in progress, such as asset tracking, dash cameras, PDAs and handhelds, point of sale (POS) devices and hardware for smart grid and metering deployments, Ikotek’s core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT at scale.
Led by Chief Executive Officer, Joe Peterson, who has more than 27 years of diverse experience across cellular and IoT industries in the US and international, Ikotek has gathered a team of industry veterans to amplify its vision of becoming the world’s most trusted IoT ODM. Recent additions to the US-based executive management team include:
Bill Leunis, the Vice President of Finance, who brings extensive experience in finance, operations and general management in manufacturing and EMS organizations. Previously, he has headed Finance in divisions of large multi-national corporations ranging in size from 500 to 20,000 people. In addition, he has served as CFO of a company, leading all aspects from its acquisition to IPO for eight years after going public.
Tim Newberg, the Vice President of Sales for the US and Canada, has joined with more than 25 years of experience and leadership in the wireless, broadband, consumer electronics and massive IoT industries. From hardware and software strategy to product marketing, sales and business development he has held senior executive positions at companies including Texas Instruments, Broadcom, Sequans, Rootmetrics, Polte and Sercomm.
Steve Burrington, the Head of North America Engineering, is a 25-year veteran of large and medium-sized wireless product development teams. Previously he served as Vice President of Engineering at CalAmp for the company’s telematics products. He has extensive experience of getting a diverse range of products to market, via organic development and JDM partnerships. In addition, he has held Vice President of Engineering roles at Netgear and Sierra Wireless.
These additions to the Ikotek management team have been supported by hires across the business and Ikotek now has more than 350 dedicated R&D employees and continues to add employees on a weekly basis.
“We’ve seen an incredible uptake of new customers over the last year and we’re excited to bring our unique ODM capabilities and advantages to customers,” said Peterson. “Supporting our customers with quick time-to-market, leading IoT industry expertise and cost-effective services and solutions is critical during a time where digital transformation is growing across all industries. To help manage growth, commercial excellence and new customers, I’m thrilled to welcome these three leading IoT and ODM capacities to our management team. We aim to serve our customers with local experts in North America and Europe and APAC so we can ensure that Ikotek is close to our customers and has local understanding of their needs.”
Ikotek targets mid-market IoT customers in response to increased demand for the design and build of products. The company’s ethos is to give customers a competitive advantage, through cost reductions and enable substantial savings to be achieved on their device design, manufacturing and certification costs. In addition, Ikotek is focused on taking customers’ projects from idea to market in record breaking time. In less than three months, Ikotek has provided end-to-end ODM services that took a complex IoT device to market including design, development and manufacturing.
“Ikotek exists to turn our customers’ device dreams into IoT reality,” Peterson added, pointing out the ways in which the company can help are listed on www.ikotek.com. “We’re keen to become customers’ indispensable partner in taking their innovations from concept to high volume product launches across global markets.”
About Ikotek
Ikotek is The IoT ODM. With a wide variety IoT projects currently underway, our core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT. We cover technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
